NovaBridge Biosciences (NBP) Cash from Financing Activities (2019 - 2025)

NovaBridge Biosciences (NBP) reported Cash from Financing Activities of $57.7 million for Q4 2025, up 1604.82% quarter-over-quarter from -$3.8 million in Q3 2024.

NovaBridge Biosciences (NBP) Cash from Financing Activities (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has 4 years of Cash from Financing Activities data on file, last reported at $57.7 million in Q4 2025.

  • Cash from Financing Activities for Q4 2025 came in at $57.7 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $53.9 million (down 86.67% YoY), and the FY2025 annual result was $57.7 million, up 1483.96% from the prior year.
  • Cash from Financing Activities improved to $57.7 million in Q4 2025 per NBP's latest filing, from -$3.8 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $57.7 million in Q4 2025 and troughed at -$3.8 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
2 Belite Bio 55,234.00 Bn 55,234.00 Bn - -
3 Quantum Biopharma 17,823.14 Bn 17,823.14 Bn - 7.00 Mn
4 Legend Biotech 3,624.50 Bn 3,624.21 Bn 242.10 Mn -600,000.00
5 Akari Therapeutics 1,745.73 Bn 1,745.73 Bn - 53,000.00
6 Evaxion A 1,540.85 Bn 1,540.84 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 112.57 Bn 105.33 Bn 2.59 Bn -538.80 Mn
9 Abivax 93.46 Bn 93.46 Bn - 85,464.43
10 NovaBridge Biosciences 331.49 Mn 120.65 Mn - 57.73 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 57.73 Mn
Dec 31, 2025 57.73 Mn
Sep 30, 2024 -3.84 Mn
Sep 30, 2024 -3.84 Mn
Dec 31, 2020 127.47 Mn
Dec 31, 2020 127.47 Mn
Sep 30, 2020 280.56 Mn
Sep 30, 2020 280.56 Mn
Dec 31, 2019 16.07 Mn
Dec 31, 2019 16.07 Mn